Ismail S A, Park H W
Department of Molecular Sciences, University of Tennessee Health Science Center, USA.
Acta Crystallogr D Biol Crystallogr. 2005 Nov;61(Pt 11):1508-13. doi: 10.1107/S0907444905026740. Epub 2005 Oct 19.
The crystal structure of human liver glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been determined. This structure represents the first moderate-resolution (2.5 A) and crystallographically refined (Rfree = 22.9%) human GAPDH structure. The liver GAPDH structure consists of a homotetramer, each subunit of which is bound to a nicotinamide adenine dinucleotide (NAD+) molecule. The GAPDH enzyme has glycolytic and non-glycolytic functions, both of which are of chemotherapeutic interest. The availability of a high-quality human GAPDH structure is a necessity for structure-based drug design. In this study, structural differences between human liver and skeletal muscle GAPDHs are reported in order to understand how these two enzymes might respond to anti-trypanosomatid GAPDH inhibitors.
已确定人肝脏甘油醛-3-磷酸脱氢酶(GAPDH)的晶体结构。该结构代表首个中等分辨率(2.5埃)且经晶体学精修(Rfree = 22.9%)的人GAPDH结构。肝脏GAPDH结构由一个同四聚体组成,其每个亚基均与一个烟酰胺腺嘌呤二核苷酸(NAD+)分子结合。GAPDH酶具有糖酵解和非糖酵解功能,这两种功能在化疗方面均具有研究意义。高质量人GAPDH结构的可得性是基于结构的药物设计所必需的。在本研究中,报告了人肝脏和骨骼肌GAPDH之间的结构差异,以便了解这两种酶可能如何对抗锥虫GAPDH抑制剂作出反应。